scholarly journals Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia

2019 ◽  
Vol 116 (49) ◽  
pp. 24593-24599 ◽  
Author(s):  
Anupriya Agarwal ◽  
William J. Bolosky ◽  
David B. Wilson ◽  
Christopher A. Eide ◽  
Susan B. Olson ◽  
...  

Hematopoiesis, the formation of blood cells, involves the hierarchical differentiation of immature blast cells into mature, functional cell types and lineages of the immune system. Hematopoietic stem cells precisely regulate self-renewal versus differentiation to balance the production of blood cells and maintenance of the stem cell pool. The canonical view of acute myeloid leukemia (AML) is that it results from a combination of molecular events in a hematopoietic stem cell that block differentiation and drive proliferation. These events result in the accumulation of primitive hematopoietic blast cells in the blood and bone marrow. We used mathematical modeling to determine the impact of varying differentiation rates on myeloblastic accumulation. Our model shows that, instead of the commonly held belief that AML results from a complete block of differentiation of the hematopoietic stem cell, even a slight skewing of the fraction of cells that differentiate would produce an accumulation of blasts. We confirmed this model by interphase fluorescent in situ hybridization (FISH) and sequencing of purified cell populations from patients with AML, which showed that different leukemia-causing molecular abnormalities typically thought to block differentiation were consistently present in mature myeloid cells such as neutrophils and monocytes at similar levels to those in immature myeloid cells. These findings suggest reduced or skewed, rather than blocked, differentiation is responsible for the development of AML. Approaches that restore normal regulation of hematopoiesis could be effective treatment strategies.

JBMTCT ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 15-18
Author(s):  
Yhasmine Delles Oliveira Garcia ◽  
Juliene Lima Mesquita ◽  
Yensy Mariana Zelaya Rosales ◽  
Anna Thawanny Gadelha Moura ◽  
Beatriz Stela Gomes de Sousa Pitombeira Araujo ◽  
...  

Secondary Acute Myeloid Leukemia (s-AML) refers to the development of leukemia after cytotoxic therapy, immunosuppressive therapy, radiation or an antecedent hematological disorder, such as Myelodysplastic Syndrome (MDS). A s-AML corresponds to 10% to 30% of AML cases and is defined by the presence of at least 20% of blast cells, representing a category of disease with a poor prognosis. Allogeneic hematopoietic stem cell transplan­tation (Allo-HSCT) is the only option with curative potential for patients with s-AML, but recurrence after HSCT emerges as a frequent cause of treatment failure and course with high mortality. We report the case of a patient with s-AML after MDS, who underwent HSCT due to refractoriness to other treatments, recovering the bone marrow with dysplasia, be­ing classified as AREB1.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3066-3066
Author(s):  
Xiao Jun Huang ◽  
Yu Wang

Abstract Abstract 3066 Background. The impact of risk-related parameters has not been defined in transplant settings. Design and methods. We analyzed the data of 255 consecutive patients (median age: 26) with acute myeloid leukemia (AML) in their first or second remission (CR1 or CR2) after haploidentical hematopoietic stem cell transplantation (HSCT). Results. Three parameters were found to be predictive of outcome: response after induction therapy, WBC count at diagnosis, and cytogenetics. These three factors were combined to yield two risk groups. The 2-year cumulative incidences of relapse for patients at low and high risk were 8% and 36% (p = 0.001), respectively. The three-year probabilities of leukemia-free survival (LFS) for these two groups were 80% and 52% (p = 0.001), respectively. Multivariate analysis for relapse and for LFS showed that not achieving CR after 2 courses of therapy was the strongest independent prognostic factor (p=0.001, and p=0.019, respectively). In addition, in a subgroup of patients with quantification of minimal residual disease (MRD) at the time of HSCT, positive MRD at this time point was correlated with a poor outcome. Conclusions. Our results suggest that the index is simple and predictive, so it might be applied to assist with risk-directed post-transplant therapy for young patients with AML in CR who have received myeloablative haploidentical HSCT. Disclosures: No relevant conflicts of interest to declare.


Author(s):  
Linus Angenendt ◽  
Isabel Hilgefort ◽  
Jan-Henrik Mikesch ◽  
Bernhard Schlüter ◽  
Wolfgang E. Berdel ◽  
...  

AbstractLow intake of magnesium has been associated with the occurrence of lymphomas and decreased magnesium levels suppress the cytotoxic function of T cells and natural killer cells in patients with “X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia” (XMEN) syndrome. These cell types are also important mediators of immune-mediated effects after allogeneic hematopoietic stem cell transplantation. Here, we show that high posttransplant magnesium levels independently associate with a lower incidence of relapse, a higher risk of acute graft-versus-host disease, and a higher non-relapse mortality in 368 patients with acute myeloid leukemia from our center. Magnesium serum levels might impact on donor-cell-mediated immune responses in acute myeloid leukemia.


Sign in / Sign up

Export Citation Format

Share Document